1441673-92-2

Basic information

• Product Name: ledipasvir interMediate
• Synonyms: potassiuM (S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylate;(6S)-5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid 5-(1,1-dimethylethyl) ester potassium salt (1:1);(6S)-5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid 5-(1,1-diMethylethyl) ester;(6S)-5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid 5-(1,1-diMethylethyl) ester potassiuM salt;edipasvir interMediate;Ledipasvir INT 1;5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 5-(1,1-dimethylethyl) ester, potassium salt (1:1), (6S)-;5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 5-(1,1-dimethylethyl) ester, potassium salt, (6S)-
• CAS NO: 1441673-92-2
• Molecular Formula: C₁₂H₁₈NO₄*K
• Molecular Weight: 241.28356
• EINECS: -0
• Mol File: 1441673-92-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: ledipasvir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: ledipasvir interMediate(1441673-92-2)
• EPA Substance Registry System: ledipasvir interMediate(1441673-92-2)

Safety Data

• Hazardous Substances Data: 1441673-92-2(Hazardous Substances Data)

Usage

General Description

Ledipasvir intermediate is an important chemical compound in the synthesis of the antiviral medication ledipasvir, which is used in the treatment of chronic hepatitis C virus infection. The intermediate compound is a key building block in the synthesis of ledipasvir, and it plays a crucial role in the production of the final drug product. Chemical intermediates like ledipasvir intermediate are essential in the pharmaceutical industry for the efficient and cost-effective production of complex drugs, and they are carefully designed and manufactured to meet strict quality and purity standards. Ledipasvir intermediate is a critical component in the synthesis of ledipasvir, contributing to the overall effectiveness and safety of the medication for the treatment of hepatitis C infection.

Upstream product

• 81469-31-0 1-(hydroxymethyl)-1-(iodomethyl)cyclopropane 
• 1129634-44-1 (6S)-5-[(tert-butoxy)carbonyl]-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1454843-77-6 (±)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 83321-23-7 1,1-bis(iodomethyl)cyclopropane 
• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 

Downstream Products

• 1499193-61-1 (S)-6-(2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl) 5-tert-butyl 5-azaspiro[2.4]heptane-5,6-dicarboxylate 
• 1441670-89-8 (6S)-6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester 

Relevant articles and documents

(S)- 5 - R - 5 - azaspiro [2, 4] heptane -6 - carboxylic acid

The invention relates to a preparation method of (S)-5-R-5-azaspiro (2,4) heptane-6-carboxylic acid which is a compound as shown in a formula (III). The preparation method comprises the following steps: dissolving a compound 5 in an inert solvent and adding alkali to perform reaction (5), wherein LG is a leaving group and R is an amino-protecting group. The reaction provided by the invention can be performed by chiral synthesis, the yield is above 75% and the total yield is about 50%. The high performance liquid chromatography (HPLC) purity of the product is above 99%, the ee is more than 98%, chiral separation is not required, the yield is greatly improved and the cost is reduced.